Abstract
The thyrotropin [thyroid-stimulating hormone (TSH)] receptor (TSHR) is known to acutely and persistently stimulate cAMP signaling and at higher TSH concentrations to acutely stimulate phosphoinositide signaling. We measured persistent signaling by stimulating TSHR-expressing human embryonic kidney-EM293 cells with TSH and measuring cAMP or inositol monophosphate (IP1) production, a measure of phosphoinositide signaling, 60 min or longer after TSH removal. In contrast to persistent cAMP production, persistent IP1 production increased progressively when TSH exposure was increased from 1 to 30 min, whereas the rates of decay of persistent signaling were similar. A small-molecule agonist and a thyroid-stimulating antibody also caused persistent IP1 and cAMP signaling. A small-molecule inverse agonist and a neutral antagonist inhibited TSH-stimulated persistent IP1 production, whereas the inverse agonist but not the neutral antagonist inhibited persistent cAMP production. As with persistent cAMP production, persistent IP1 production was not affected when TSHR internalization was inhibited or enhanced. Moreover, Alexa546-TSH-activated TSHR internalization was not accompanied by Gαq coupling protein internalization. Thus, transient exposure to high concentrations of TSH causes persistent phosphoinositide and cAMP signaling that is not dependent on internalization. To our knowledge, this is the first demonstration of persistent activation by any G protein-coupled receptor (GPCR) via the Gαq pathway and of two G protein-mediated pathways by any GPCR.
Footnotes
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported by the Intramural Research Programs of the National Institute of Diabetes and Digestive and Kidney Diseases [Grants Z01-DK011006, Z01-DK047045]; the National Human Genome Research Institute; and the Molecular Libraries Initiative of the Roadmap for Medical Research, National Institutes of Health.
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.111.072157.
-
ABBREVIATIONS:
- GPCR
- G protein-coupled receptor
- TSH
- thyroid-stimulating hormone
- TSHR
- thyroid-stimulating hormone receptor
- IP1
- inositol monophosphate
- I-1,4,5-P3
- inositol-1,4,5-trisphosphate
- YFP
- yellow fluorescent protein
- HBSS
- Hanks' balanced salt solution
- IBMX
- 3-isobutyl-1-methylxanthine
- HEK
- human embryonic kidney
- βArr2
- β-arrestin-2
- NCGC00161870
- N-[4-]]5-]3-(furan-2-ylmethyl)-4-oxo-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]phenyl]acetamide
- NCGC00161856
- 2-[3-[(2,6-dimethylphenoxy)methyl]-4-methoxyphenyl]-3-(furan-2-ylmethyl)-1,2-dihydroquinazolin-4-one
- NCGC00229600
- 2-(3-((2,6-dimethylphenoxy)methyl)-4-methoxyphenyl)-3-(pyridin-3-ylmethyl)-2,3-dihydroquinazolin-4(1H)-one.
- Received March 8, 2011.
- Accepted April 26, 2011.
- U.S. Government work not protected by U.S. copyright
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|